Dash Bio

At Dash Bio, we're revolutionizing bioanalysis to expedite drug development. By leveraging robotics and modern software, we deliver higher-quality assays with turnaround times up to 10x faster than the industry average, scaling seamlessly from preclinical through late-stage clinical studies. While drug discovery has been revolutionized with AI and breakthrough modalities, the development phase remains bogged down by manual, labor-intensive processes. We're changing that narrative. Our tech-first products automate critical steps, reducing costs and time to market while improving quality of results. Meet Our Leadership Team: Dave Johnson, CEO: Former Chief Data and AI Officer at Moderna. Ander Tallett, COO: Led Enterprise Systems at Moderna and Resilience. Ely Porter, CSO: Co-founder and CTO of Rootpath. Together, we're crafting a future where bioanalysis is intuitive, data flows effortlessly, and drugs reach the market faster than ever before. Join us on this journey. Learn more at dash.bio